Management of Ashman Phenomenon in Patients with Atrial Fibrillation

Understanding Ashman Phenomenon

Ashman phenomenon is an aberrant ventricular conduction that occurs during atrial fibrillation, typically after a short cardiac cycle follows a long cycle, representing a functional bundle branch block rather than a primary ventricular arrhythmia, and is directly related to rate irregularity in AF 1, 2

The American College of Cardiology recommends control of ventricular rate using a beta blocker or nondihydropyridine calcium channel antagonist as the primary approach for patients with AF, including those experiencing Ashman phenomenon, with a goal of resting heart rate <80 bpm for symptomatic management 1
For patients already on amiodarone, adding a beta blocker is recommended for controlling both resting and exercise heart rate, with metoprolol tartrate 25-100 mg twice daily as a preferred option 3

For hemodynamically stable patients, adding a beta blocker to existing amiodarone therapy is recommended, with other options including metoprolol succinate, bisoprolol, or carvedilol 3
If beta blockers are contraindicated or insufficient, nondihydropyridine calcium channel blockers or digoxin can be used, especially in patients with heart failure 3

Amiodarone is already useful for ventricular rate control in AF, but may not be sufficient alone, and oral amiodarone may be useful for ventricular rate control when other measures are unsuccessful or contraindicated (Class IIb recommendation) 1, 4
When using amiodarone with beta blockers, start with lower doses of beta blockers to avoid bradycardia due to drug interactions, and monitor for drug interactions, as amiodarone can increase the effects of beta blockers and digoxin 3

In patients with pre-excitation and AF, digoxin, nondihydropyridine calcium channel antagonists, or intravenous amiodarone should not be administered as they may increase ventricular response and potentially result in ventricular fibrillation 4
Dronedarone should not be used to control ventricular rate in patients with permanent AF as it increases the risk of adverse cardiovascular outcomes 4

Regular ECG monitoring to assess the effectiveness of rate control and presence of Ashman phenomenon is recommended 1